United Therapeutics (NASDAQ:UTHR) Given New $315.00 Price Target at Bank of America

United Therapeutics (NASDAQ:UTHR) had its price target reduced by analysts at Bank of America from $321.00 to $315.00 in a report released on Wednesday,Benzinga reports. The firm currently has a “neutral” rating on the biotechnology company’s stock. Bank of America‘s price target indicates a potential upside of 10.09% from the company’s current price.

A number of other brokerages have also recently weighed in on UTHR. Cantor Fitzgerald initiated coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They set an “overweight” rating and a $405.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Wells Fargo & Company reissued an “equal weight” rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. JPMorgan Chase & Co. dropped their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating on the stock in a report on Thursday, May 1st. Finally, Morgan Stanley raised their price objective on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an “equal weight” rating in a report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $393.08.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $286.14 on Wednesday. United Therapeutics has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market cap of $12.91 billion, a PE ratio of 12.57, a PEG ratio of 0.97 and a beta of 0.57. The firm’s 50 day moving average price is $300.43 and its two-hundred day moving average price is $331.51.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. During the same period last year, the firm earned $6.17 earnings per share. The business’s revenue for the quarter was up 17.2% on a year-over-year basis. As a group, sell-side analysts predict that United Therapeutics will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In other United Therapeutics news, CFO James Edgemond sold 12,000 shares of the business’s stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $325.37, for a total value of $3,904,440.00. Following the completion of the sale, the chief financial officer now owns 8,118 shares of the company’s stock, valued at $2,641,353.66. The trade was a 59.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the business’s stock in a transaction dated Thursday, May 29th. The shares were sold at an average price of $316.07, for a total transaction of $3,476,770.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares of the company’s stock, valued at $11,625,370.67. This represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,500 shares of company stock valued at $20,828,390 in the last quarter. Company insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the 4th quarter valued at approximately $25,000. Savant Capital LLC raised its position in shares of United Therapeutics by 2.7% in the 4th quarter. Savant Capital LLC now owns 10,205 shares of the biotechnology company’s stock valued at $3,601,000 after buying an additional 266 shares in the last quarter. Louisiana State Employees Retirement System raised its position in shares of United Therapeutics by 0.8% in the 4th quarter. Louisiana State Employees Retirement System now owns 12,400 shares of the biotechnology company’s stock valued at $4,375,000 after buying an additional 100 shares in the last quarter. AustralianSuper Pty Ltd raised its position in shares of United Therapeutics by 577.1% in the 4th quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock valued at $66,962,000 after buying an additional 161,751 shares in the last quarter. Finally, Principal Securities Inc. raised its position in shares of United Therapeutics by 14.2% in the 4th quarter. Principal Securities Inc. now owns 2,174 shares of the biotechnology company’s stock valued at $767,000 after buying an additional 270 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.